Trade Rhythm Pharmaceuticals Inc - RYTM CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.26 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 49.18 |
| Open | 48.99 |
| 1-Year Change | 90.77% |
| Day's Range | 47.6 - 48.99 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 11, 2024 | 49.18 | 1.02 | 2.12% | 48.16 | 49.44 | 47.00 |
| Sep 10, 2024 | 49.05 | -1.50 | -2.97% | 50.55 | 50.64 | 48.12 |
| Sep 9, 2024 | 50.62 | 1.39 | 2.82% | 49.23 | 50.92 | 49.19 |
| Sep 6, 2024 | 49.19 | 1.99 | 4.22% | 47.20 | 49.47 | 47.20 |
| Sep 5, 2024 | 48.24 | 1.40 | 2.99% | 46.84 | 48.26 | 46.27 |
| Sep 4, 2024 | 46.80 | 1.83 | 4.07% | 44.97 | 46.87 | 44.95 |
| Sep 3, 2024 | 45.83 | -0.65 | -1.40% | 46.48 | 47.56 | 45.09 |
| Aug 30, 2024 | 47.23 | 1.63 | 3.57% | 45.60 | 47.30 | 45.60 |
| Aug 29, 2024 | 45.95 | -0.50 | -1.08% | 46.45 | 47.19 | 45.62 |
| Aug 28, 2024 | 46.32 | -0.69 | -1.47% | 47.01 | 47.40 | 45.57 |
| Aug 27, 2024 | 47.37 | -2.06 | -4.17% | 49.43 | 49.44 | 46.94 |
| Aug 26, 2024 | 49.90 | 3.74 | 8.10% | 46.16 | 50.01 | 46.16 |
| Aug 23, 2024 | 46.06 | 1.78 | 4.02% | 44.28 | 46.15 | 44.05 |
| Aug 22, 2024 | 44.15 | -0.80 | -1.78% | 44.95 | 45.39 | 43.48 |
| Aug 21, 2024 | 45.23 | 0.09 | 0.20% | 45.14 | 46.52 | 45.06 |
| Aug 20, 2024 | 45.52 | -0.34 | -0.74% | 45.86 | 47.83 | 44.62 |
| Aug 19, 2024 | 47.00 | 1.34 | 2.93% | 45.66 | 47.25 | 45.66 |
| Aug 16, 2024 | 45.99 | -0.07 | -0.15% | 46.06 | 46.59 | 45.58 |
| Aug 15, 2024 | 46.65 | 0.26 | 0.56% | 46.39 | 47.27 | 46.02 |
| Aug 14, 2024 | 45.74 | 0.61 | 1.35% | 45.13 | 45.89 | 44.57 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Rhythm Pharma Company profile
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing treatment for genetic diseases of obesity, which are characterized by early-onset, severe obesity and an insatiable hunger (hyperphagia). Its lead product candidate, IMCIVREE (setmelanotide), is a potent melanocortin-4 receptor (MC4R). IMCIVREE is developed for the treatment of rare genetic diseases of obesity. It is focused on the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating weight and hunger. It targets the MC4R pathway to develop therapeutics for rare genetic diseases of obesity, including proopiomelanocortin (POMC) deficiency obesity, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl syndrome (BBS), Alstrom syndrome, POMC or LEPR heterozygous deficiency obesity, Smith-Magenis syndrome, steroid receptor coactivator 1 (SRC1) deficiency obesity, MC4R deficiency obesity and SH2B adapter protein 1 (SH2B1) deficiency obesity.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Rhythm Pharmaceuticals Inc revenues increased from $0K to $3.2M. Net loss decreased 48% to $69.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$3.04 to -$1.40.
| Industry: | Bio Therapeutic Drugs |
222 Berkeley Street
12th Floor Boston
BOSTON
MASSACHUSETTS 02116
US
News
ECB Preview: cuts expected but the pace is uncertain
Markets expect the ECB to cut rates again in September, but how many more?
12:34, 11 September 2024
Market analysis: US CPI and PPI
Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.
07:56, 10 September 2024
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024
Jackson Hole Preview: All eyes on Powell and Gold
The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.
15:24, 19 August 2024
All eyes on inflation: US and UK CPI take centre stage
Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.
14:41, 13 August 2024
European stocks face resistance in their attempt to recover
European stocks struggle to recover as the tech sector faces continued downside pressure in Asia.
13:56, 9 August 2024
Global selloff continues on US economy fears
Thursday’s rise in jobless claims led to a market meltdown in the US stock market as investors became concerned that the Federal Reserve made the wrong decision by keeping rates unchanged on Wednesday.
14:40, 5 August 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com